Sanofi Consumer Healthcare India Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Sanofi Consumer Healthcare India rose 39.78% to Rs 62.90 crore in the quarter ended September 2025 as against Rs 45.00 crore during the previous quarter ended September 2024. Sales rose 46.28% to Rs 233.90 crore in the quarter ended September 2025 as against Rs 159.90 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

On a standalone basis, revenue from operations stood at Rs 233.9 crore, up 46% year-on-year and 6% sequentially, driven by exports and domestic business.

Domestic sales grew 20% YoY, while exports surged more than tenfold due to a low base.

Profit before tax (PBT) increased 37.4% YoY to Rs 84.1 crore in Q3 CY25, and was up 6.59% sequentially. Profit after tax (PAT) came in at Rs 62.9 crore, up 40% year-on-year and 4% sequentially.

On the cost side, total expenses rose 50.2% YoY to Rs 152.8 crore. Cost of materials consumed was Rs 36.5 crore, up 159% YoY, while employee expenses rose to Rs 31.7 crore, up 16% YoY.

Quarter figures are not directly comparable due to the demerger and voluntary recall of certain variants of key brands in the domestic market.

Managing director Himanshu Bakshi said, Our third-quarter results reflect the strength of our diversified portfolio driving sustained growth momentum this quarter. The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year. Anchored in science and guided by purpose, we remain committed to making self-care simpler, more accessible and more effective for every consumer.

Sanofi Consumer Healthcare India Limited (SCHIL) has emerged as a distinct legal entity following its demerger from Sanofi India. It now operates as an independent entity with a focused mandate in the consumer healthcare segment.

Powered by Capital Market - Live News

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 12 November 2025.

Powered by Capital Market - Live News

According to the company's regulatory filing, Naidu?s resignation will be effective from the close of business hours on 15 October 2025, which will be his last working day with the company.

Sanofi Consumer Healthcare India officially demerged from Sanofi India on 1 June 2024 and now operates as an independent entity focused solely on the consumer healthcare segment. Its key product categories include allergy care, digestive wellness, pain relief, multivitamins, and herbal/traditional supplements, with flagship brands such as Allegra, DePURA, Avil, and Combiflam anchoring its portfolio.

The company reported a 28% year-on-year rise in revenue to Rs 220.9 crore in Q2 2025, powered by export operations and successful product launches. On a sequential basis, the company?s revenue rose 27.5% from Rs 172.6 crore in Q1 2025. Profit after tax (PAT) for the quarter stood at Rs 60.7 crore, marking a 21% increase over Q1FY25 and a 109% surge from Rs 29 crore in Q2 2024.

The scrip declined 0.84% to Rs 4,624 on the BSE.

Powered by Capital Market - Live News